CoChat
Sign Up
Cited by 26

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Interaction between therapeutic interventions for Alzheimer’s disease and physiological Aβ clearance mechanisms

Morrone, Christopher D., Liu, Mingzhe, Black, Sandra E., McLaurin, JoAnne·2015·Frontiers in Aging Neuroscience
DOI 10.3389/fnagi.2015.00064PMC PMC4419721
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnagi.2015.00064

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 32 references

Research works printed but not linked: 159

  1. Akiyama H. Barger S. Barnum S. Bradt B. Bauer J. Cole G. M.. (2000). Inflammation and Alzheimer’s disease. Neurobiol. Aging 21, 383– 421. 10.1016/S0197-4580(00)00124-X 10858586 PMC3887148 · DOI · Paper page
  2. Aliev G. Ashraf G. M. Kaminsky Y. G. Sheikh I. A. Sudakov S. K. Yakhno N. N.. (2013). Implication of the nutritional and nonnutritional factors in the context of preservation of cognitive performance in patients with dementia/depression and Alzheimer disease. Am. J. Alzheimers Dis. Other Demen. 28, 660– 670. 10.1177/1533317513504614 24085255 PMC10852765 · DOI
  3. Arbel-Ornath M. Hudry E. Eikermann-Haerter K. Hou S. Gregory J. L. Zhao L.. (2013). Interstitial fluid drainage is impaired in ischemic stroke and Alzheimer’s disease mouse models. Acta Neuropathol. 126, 353– 364. 10.1007/s00401-013-1145-2 23818064 PMC3810119 · DOI
  4. Arcoverde C. Deslandes A. Moraes H. Almeida C. Araujo N. B. Vasques P. E.. (2014). Treadmill training as an augmentation treatment for Alzheimer’s disease: a pilot randomized controlled study. Arq. Neuropsiquiatr. 72, 190– 196. 10.1590/0004-282x20130231 24676435 · DOI
  5. Banks W. A. Terrell B. Farr S. A. Robinson S. M. Nonaka N. Morley J. E. (2002). Passage of amyloid beta protein antibody across the blood brain barrier in a mouse model of Alzheimer’s disease. Peptides 23, 2223– 2226. 10.1016/S0196-9781(02)00261-9 12535702 · DOI
  6. Baño Otalora B. Popovic N. Gambini J. Popovic M. Viña J. Bonet-Costa V.. (2012). Circadian system functionality, hippocampal oxidative stress and spatial memory in the APPswe/PS1dE9 transgenic model of Alzheimer disease: effects of melatonin or ramelteon. Chronobiol. Internat. 29, 822– 834. 10.3109/07420528.2012.699119 22823866 · DOI
  7. Barnard N. D. Bush A. I. Ceccarelli A. Cooper J. de Jager C. A. Erickson K. I.. (2014). Dietary and lifestyle guidelines for the prevention of Alzheimer’s disease. Neurobiol. Aging 35(Suppl. 2), S74– S78. 10.1016/j.neurobiolaging.2014.03.033 24913896 · DOI
  8. Benedict C. Byberg L. Cedernaes J. Hogenkamp P. S. Giedratis V. Kilander L.. (2014). Self-reported sleep disturbance is associated with Alzheimer’s disease risk in men. Alzheimers Dement. [Epub ahead of print]. 10.1016/j.jalz.2014.08.104 25438949 · DOI
  9. Biessels G. J. Staekenborg S. Brunner E. Brayne C. Scheltens P. (2006). Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 5, 64– 74. 10.1016/s1474-4422(05)70284-2 16361024 · DOI · Paper page
  10. Black S. E. Gao F. Bilbao J. (2009). Understanding white matter disease: imaging-pathological correlations in vascular cognitive impairment. Stroke 40(Suppl. 3), S48– S52. 10.1161/strokeaha.108.537704 19064767 · DOI · Paper page
  11. Britsch S. (2007). The Neuregulin-I/ErbB Signaling System in Development and Disease (Vol. 190). Berlin: Springer Science and Business Media. 17432114
  12. Carare R. O. Bernardes-Silva M. Newman T. A. Page A. M. Nicoll J. A. R. Perry V. H.. (2008). Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol. Appl. Neurobiol. 34, 131– 144. 10.1111/j.1365-2990.2007.00926.x 18208483 · DOI · Paper page
  13. Ciccone M. M. Scicchitano P. Zito A. Cortese F. Boninfante B. Falcone V. A.. (2014). Correlation between inflammatory markers of atherosclerosis and carotid intima-media thickness in obstructive sleep Apnea. Molecules 19, 1651– 1662. 10.3390/molecules19021651 24481114 PMC6271201 · DOI
  14. Cipriani G. Lucetti C. Danti S. Nuti A. (2014). Sleep disturbances and dementia. Psychogeriatrics 15, 65– 74 10.1111/psyg.12069 25515641 · DOI
  15. Coogan A. N. Schutová B. Husung S. Furczyk K. Baune B. T. Kropp P.. (2013). The circadian system in Alzheimer’s disease: disturbances, mechanisms and opportunities. Biol. Psychiatry 74, 333– 339. 10.1016/j.biopsych.2012.11.021 23273723 · DOI
  16. Cooke J. R. Ancoli-Israel S. Liu L. Loredo J. S. Natarajan L. Palmer B. S.. (2009). Continuous positive airway pressure deepens sleep in patients with Alzheimer’s disease and obstructive sleep apnea. Sleep Med. 10, 1101– 1106. 10.1016/j.sleep.2008.12.016 19699148 PMC2783482 · DOI
  17. Cserr H. F. Cooper D. N. Suri P. K. Patlak C. S. (1981). Efflux of radiolabeled polyethylene glycols and albumin from rat brain. Am. J. Physiol. 240, F319– F328. 7223889
  18. Daulatzai M. A. (2012). Quintessential risk factors: their role in promoting cognitive dysfunction and Alzheimer’s disease. Neurochem. Res. 37, 2627– 2658. 10.1007/s11064-012-0854-6 22886562 · DOI
  19. de Andrade L. P. Gobbi L. T. B. Coelho F. G. M. Christofoletti G. Costa J. L. R. Stella F. (2013). Benefits of multimodal exercise intervention for postural control and frontal cognitive functions in individuals with Alzheimer’s disease: a controlled trial. J. Am. Geriatr. Soc. 61, 1919– 1926. 10.1111/jgs.12531 24219193 · DOI
  20. Deanne R. Wu Z. Sagare A. Davis J. Du Yan S. Hamm K.. (2004). LRP/amyloid-beta peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 45, 333– 344. 10.1016/j.neuron.2004.07.017 15294142 · DOI · Paper page
  21. Deckers K. van Boxtel M. P. J. Schiepers O. J. G. de Vugt M. Muñoz Sánchez J. L. Anstey K. J.. (2015). Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. Int. J. Geriatr. Psychiatry 30, 234– 246. 10.1002/gps.4245 25504093 · DOI · Paper page
  22. DeMattos R. B. Bales K. R. Cummins D. J. Paul S. M. Holtzman D. M. (2002). Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science 295, 2264– 2267. 10.1126/science.1067568 11910111 · DOI · Paper page
  23. Di Meco A. Joshi Y. B. Praticò D. (2014). Sleep deprivation impairs memory, tau metabolism and synaptic integrity of a mouse model of Alzheimer’s disease with plaques and tangles. Neurobiol. Aging 35, 1813– 1820. 10.1016/j.neurobiolaging.2014.02.011 24629673 · DOI · Paper page
  24. Donahue J. E. Flaherty S. L. Johanson C. E. Duncan J. A. 3rd Silverberg G. D. Miller M. C.. (2006). RAGE, LRP-1 and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol. 112, 405– 415. 10.1007/s00401-006-0115-3 16865397 · DOI · Paper page
  25. Dorr A. Sahota B. Chinta L. V. Brown M. E. Lai A. Y. Ma K.. (2012). Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer’s disease. Brain 135(Pt. 10), 3039– 3050. 10.1093/brain/aws243 23065792 · DOI
  26. Farlow M. Arnold S. E. van Dyck C. H. Aisen P. S. Snider B. J. Porsteinsson A. P.. (2012). Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement. 8, 261– 271. 10.1016/j.jalz.2011.09.224 22672770 · DOI
  27. Farris W. Mansourian S. Chang Y. Lindsley L. Eckman E. A. Frosch M. P.. (2003). Insulin-degrading enzyme regulates the levels of insulin, amyloid-beta-protein and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U S A 100, 4162– 4167. 10.1073/pnas.0230450100 12634421 PMC153065 · DOI
  28. Farris W. Mansourian S. Leissring M. A. Eckman E. A. Bertram L. Eckman C. B.. (2004). Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid β-protein. Am. J. Pathol. 164, 1425– 1434. 10.1016/s0002-9440(10)63229-4 15039230 PMC1615329 · DOI · Paper page
  29. Floyd J. A. Medler S. M. Ager J. W. Janisse J. J. (2000). Age-related changes in initiation and maintenance of sleep: a meta-analysis. Res. Nurs. Health 23, 106– 117. 10.1002/(sici)1098-240x(200004)23:2<106::aid-nur3>3.0.co;2-a 10782869 · DOI
  30. Frackowiak J. Wisniewski H. M. Wegiel J. Merz G. S. Iqbal K. Wang K. C. (1992). Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol. 84, 225– 233. 10.1007/bf00227813 1414275 · DOI · Paper page
  31. Funato H. Yoshimura M. Yamazaki T. Saido T. C. Ito Y. Yokofijita J.. (1998). Astrocytes containing amyloid-b protein (Ab) positive granules are associated with Ab40-positive diffuse plaques in the aged human brain. Am. J. Pathol. 152, 983– 992. 9546359 PMC1858251
  32. Gabathuler R. (2010). Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 37, 48– 57. 10.1016/j.nbd.2009.07.028 19664710 · DOI
  33. Gaberel T. Gakuba C. Goulay R. Martinez De Lizarrondo S. Hanouz J.-L. Emery E.. (2014). Impaired glymphatic perfusion after strokes revealed by contrast-enhanced MRI: a new target for fibrinolysis? Stroke 45, 3092– 3096. 10.1161/strokeaha.114.006617 25190438 · DOI
  34. Gao F. Noor R. Keith J. Nadeau Y. Kiss A. Black S. (2012). Relationship between collagenosis of the deep medullary veins and periventricular white matter hyperintensities on magnetic resonance imaging in Alzheimer’s disease: does one size fit all? Alzheimers Dement. 8(Suppl. 4), P297 10.1016/j.jalz.2012.05.2146 · DOI
  35. Gavin A. L. Barnes N. Dijstelbloem H. M. Hogarth P. M. (1998). Cutting edge: identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity. J. Immunol. 160, 20– 23. 9551950
  36. Graf A. Riviere M. E. Caputo A. Farlow M. R. Marotta G. Sanchez-Valle R. (2014). Active Aβ immunotherapy cad106 phase ii dose-adjuvant finding study: safety and CNS biomarkers. Alzheimers Dement. 10, P274 10.1016/j.jalz.2014.04.448 · DOI
  37. Guénette S. Y. (2003). Astrocytes: a cellular player in Aβ clearance and degradation. Trends Mol. Med. 9, 279– 280. 10.1016/s1471-4914(03)00112-6 12900212 · DOI · Paper page
  38. Gustafson D. Rothenberg E. Blennow K. Steen B. Skoog I. (2003). An 18-year follow-up of overweight and risk of Alzheimer disease. Arch. Intern. Med. 163, 1524– 1528. 10.1001/archinte.163.13.1524 12860573 · DOI · Paper page
  39. Hadaczek P. Yamashita Y. Mirek H. Tamas L. Bohn M. C. Noble C.. (2006). The “perivascular pump” driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol. Ther. 14, 69– 78. 10.1016/j.ymthe.2006.02.018 16650807 PMC2730223 · DOI
  40. Haeberlein S. B. Cebers G. Höglund K. Salter H. Eketjäll S. Bogstedt A. (2013). AZD3293, a potent and selective orally active, brain-permeable BACE1 inhibitor. Alzheimers Dement. J. Alzheimers Assoc. 9: P813 10.1016/j.jalz.2013.05.1689 · DOI
  41. Han S. W. Lee S.-S. Kim S. H. Lee J. H. Kim G. S. Kim O.-J.. (2013). Effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial Doppler (ECLIPse): a multicenter, randomized, double-blind, placebo-controlled trial. Eur. Neurol. 69, 33– 40. 10.1159/000338247 23128968 · DOI
  42. Hanyu H. Hirao K. Shimizu S. Sato T. Kiuchi A. Iwamoto T. (2007). Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int. J. Geriatr. Psychiatry 22, 1264– 1266. 10.1002/gps.1851 18033677 · DOI
  43. Hardy J. Selkoe D. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353– 356. 10.1126/science.1072994 12130773 · DOI · Paper page
  44. Hawkes C. A. Deng L.-H. Fenili D. Nitz M. McLaurin J. (2012). In vivo uptake of β-amyloid by non-plaque associated microglia. Curr. Alzheimer Res. 9, 890– 901. 10.2174/156720512803251084 22272621 · DOI
  45. Hawkes C. A. Gatherer M. Sharp M. M. Dorr A. Yuen H. M. Kalaria R.. (2013). Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid-β from the mouse brain. Aging Cell 12, 224– 236. 10.1111/acel.12045 23413811 · DOI
  46. Hawkes C. A. Gentleman S. M. Nicoll J. A. Carare R. O. (2015). Prenatal high-fat diet alters the cerebrovasculature and clearance of β-amyloid in adult offspring. J. Pathol. 235, 619– 631. 10.1002/path.4468 25345857 · DOI
  47. Hawkes C. A. Jayakody N. Johnston D. A. Bechmann I. Carare R. O. (2014). Failure of perivascular drainage of β-amyloid in cerebral amyloid angiopathy. Brain Pathol. 24, 396– 403. 10.1111/bpa.12159 24946077 PMC8029317 · DOI
  48. Hoffmann K. Frederiksen K. S. Sobol N. A. Beyer N. Vogel A. Simonsen A. H.. (2013). Preserving cognition, quality of life, physical health and functional ability in Alzheimer’s disease: the effect of physical exercise (ADEX trial): rationale and design. Neuroepidemiology 41, 198– 207. 10.1159/000354632 24135720 · DOI
  49. Höglund K. Salter H. Zetterberg H. Andreason U. Olsson T. Alexander R. (2014). Monitoring the soluble amyloid precursor protein alpha (sAPPα) and beta (sAPPβ) fragments in plasma and CSF from healthy individuals treated with BACE inhibitor AZD3293 in a multiple ascending dose study: pharmacokinetic and pharmacodynamic correlate. Alzheimers Dement. J. Alzheimers Assoc. 10: P447 10.1016/j.jalz.2014.05.605 · DOI
  50. Ihara M. Nishino M. Taguchi A. Yamamoto Y. Hattori Y. Saito S.. (2014). Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study. PLoS One 9: e89516. 10.1371/journal.pone.0089516 24586841 PMC3935872 · DOI
  51. Ikeda Y. (1999). Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Thromb. Haemost. 82, 435– 438. 10605734
  52. Iliff J. J. Nedergaard M. (2013). Is there a cerebral lymphatic system? Stroke 44, S93– S95. 10.1161/STROKEAHA.112.678698 23709744 PMC3699410 · DOI
  53. Iliff J. J. Wang M. Liao Y. Plog B. A. Peng W. Gundersen G. A.. (2012). A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl. Med. 4: 147ra111. 10.1126/scitranslmed.3003748 22896675 PMC3551275 · DOI · Paper page
  54. Iwata N. Takaki Y. Fukami S. Tsubuki S. Saido T. C. (2002). Region-specific reduction of Aβ degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J. Neurosci. Res. 70, 493– 500. 10.1002/jnr.10390 12391610 · DOI
  55. Iwata N. Tsubuki S. Takaki Y. Shirotani K. Lu B. Gerard N. P.. (2001). Metabolic regulation of brain Aα by neprilysin. Science 292, 1550– 1552. 10.1126/science.1059946 11375493 · DOI
  56. Iwata N. Tsubuki S. Takaki Y. Watanabe K. Sekiguchi M. Hosoki E.. (2000). Identification of the major Abeta 1–42 degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6, 143– 150. 10.1038/72237 10655101 · DOI · Paper page
  57. Janssens J. P. Pautex S. Hilleret H. Michel J. P. (2000). Sleep disordered breathing in the elderly. Aging (Milano) 12, 417– 429. 11211951
  58. Johanson C. Flaherty S. Messier A. Duncan J. I. Silverberg G. (2006). Expression of the beta-amyloid transporter, LRP-1, in aging choroid plexus: implications for the CSF-brain system in NPH and Alzheimer’s disease. Cerebrospinal Fluid Res. 3: S29 10.1186/1743-8454-3-S1-S29 · DOI
  59. Kalaria R. N. Hedera P. (1995). Differential degeneration of the cerebral microvasculature in Alzheimer’s disease. Neuroreport 6, 477– 480. 10.1097/00001756-199502000-00018 7766847 · DOI
  60. Kang J.-E. Lim M. M. Bateman R. J. Lee J. L. Smyth L. P. Cirrito J. R.. (2009). Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle. Science 326, 1005– 1007. 10.1126/science.1180962 19779148 PMC2789838 · DOI · Paper page
  61. Kivipelto M. Solomon A. (2008). Alzheimer’s disease - the ways of prevention. J. Nutr. Health Aging 12, 89S– 94S. 10.1007/bf02982595 18165854 · DOI
  62. Kuhn P. H. Koroniak K. Hogl S. Colombo A. Zeitschel U. Willem M.. (2012). Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J. 31, 3157– 3168. 10.1038/emboj.2012.173 22728825 PMC3400020 · DOI · Paper page
  63. Kurz A. Perneczky R. (2011). Amyloid clearance as a treatment target against Alzheimer’s disease. J. Alzheimers Dis. 24, 61– 73. 10.3233/JAD-2011-102139 21422524 · DOI
  64. Kwee R. M. Kwee T. C. (2007). Virchow-Robin spaces at MR imaging. Radiographics 27, 1071– 1086. 10.1148/rg.274065722 17620468 · DOI · Paper page
  65. Lai R. Albala B. Kaplow J. M. Aluri J. Yen M. Satlin A. (2012). First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing. Alzheimers Dement. 8: P96 10.1016/j.jalz.2012.05.237 · DOI
  66. Lai A. Y. Dorr A. Thomason L. A. M. Koletar M. M. Sled J. G. Stefanovic B.. (2015). Venular degeneration leads to vascular dysfunction in a transgenic model of Alzheimer’s disease. Brain 138, 1046– 1058. 10.1093/brain/awv023 25688079 · DOI
  67. Lai A. Y. McLaurin J. (2012). Clearance of amyloid-b by microglia and macrophages: the issue of what, when and where. Future Neurol. 7, 165– 176. 10.2217/fnl.12.6 22737039 PMC3380064 · DOI
  68. Lee J. Duan W. Long J. M. Ingram D. K. Mattson M. P. (2000). Dietary restriction increases the number of newly generated neural cells and induces BDNF expression, in the dentate gyrus of rats. J. Mol. Neurosci. 15, 99– 108. 10.1385/jmn:15:2:99 11220789 · DOI
  69. Lee J. Duan W. Mattson M. P. (2002). Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J. Neurochem. 82, 1367– 1375. 10.1046/j.1471-4159.2002.01085.x 12354284 · DOI · Paper page
  70. Leissring M. A. Farris W. Chang Y. Walsh D. M. Wu X. Sun X.. (2003). Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology and premature death. Neuron 40, 1087– 1093. 10.1016/s0896-6273(03)00787-6 14687544 · DOI
  71. Liguori C. Placidi F. Albanese M. Nuccetelli M. Izzi F. Marciani M. G.. (2014). CSF beta-amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis? J. Sleep Res. 23, 420– 424. 10.1111/jsr.12130 24635662 · DOI
  72. Lim Y. Y. Pietrzak R. H. Bourgeat P. Ames D. Ellis K. A. Rembach A.. (2015). Relationships between performance on the cogstate brief battery, neurodegeneration and Aβ accumulation in cognitively normal older adults and adults with MCI. Arch. Clin. Neuropsychol. 30, 49– 58. 10.1093/arclin/acu068 25467942 · DOI
  73. Lin T.-W. Shih Y.-H. Chen S.-J. Lien C.-H. Chang C.-Y. Huang T.-Y.. (2015). Running exercise delays neurodegeneration in amygdala and hippocampus of Alzheimer’s disease (APP/PS1) transgenic mice. Neurobiol. Learn. Mem. 118, 189– 197. 10.1016/j.nlm.2014.12.005 25543023 · DOI · Paper page
  74. Liu C.-C. Kanekiyo T. Xu H. Bu G. (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106– 118. 10.1038/nrneurol.2012.263 23296339 PMC3726719 · DOI · Paper page
  75. Liu G. Yao L. Liu J. Jiang Y. Ma G. Chen Z.. (2014). Cardiovascular disease contributes to Alzheimer’s disease: evidence from large-scale genome-wide association studies. Neurobiol. Aging 35, 786– 792. 10.1016/j.neurobiolaging.2013.10.084 24231519 · DOI
  76. Lobanova I. Qureshi A. I. (2014). The association between cardiovascular risk factors and progressive hippocampus volume loss in persons with Alzheimer’s disease. J. Vasc. Interv. Neurol. 7, 52– 55. 25566342 PMC4280866
  77. Lucas F. Fukushima T. Nozaki Y. (2012). Novel BACE1 inhibitor, E2609, lowers Aβ levels in the cerebrospinal fluid and plasma in nonhuman primates. Alzheimers Dement. 8: P224 10.1016/j.jalz.2012.05.2022 · DOI
  78. Luchsinger J. A. Tang M. X. Shea S. Mayeux R. (2002). Caloric intake and the risk of Alzheimer disease. Arch. Neurol. 59, 1258– 1263. 10.1001/archneur.59.8.1258 12164721 · DOI
  79. Maki T. Okamoto Y. Carare R. O. Hase Y. Hattori Y. Hawkes C. A.. (2014). Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid. Ann. Clin. Transl. Neurol. 1, 519– 533. 10.1002/acn3.79 25356424 PMC4184555 · DOI
  80. Mandrekar S. Jiang Q. Lee C. Y. Koenigsknecht-Talboo J. Holtzman D. Landreth G. E. (2009). Microglia mediate the clearance of soluble Aβ through fluid phase macropinocytosis. J. Neurosci. 29, 4252– 4262. 10.1523/JNEUROSCI.5572-08.2009 19339619 PMC3034143 · DOI · Paper page
  81. Marques F. Sousa J. C. Sousa N. Palha J. A. (2013). Blood-brain-barriers in aging and Alzheimer’s disease. Mol. Neurosci. 8: 38. 10.1186/1750-1326-8-38 24148264 PMC4015275 · DOI
  82. Maruszak A. Pilarski A. Murphy T. Branch N. Thuret S. (2014). Hippocampal neurogenesis in Alzheimer’s disease: is there a role for dietary modulation? J. Alzheimers Dis. 38, 11– 38. 10.3233/JAD-131004 23948932 · DOI
  83. Mattson M. P. (2015). Lifelong brain health is a lifelong challenge: from evolutionary principles to empirical evidence. Ageing Res. Rev. 20, 37– 45. 10.1016/j.arr.2014.12.011 25576651 PMC4346441 · DOI
  84. McLaurin J. Kierstead M. E. Brown M. E. Hawkes C. A. Lambermon M. H. L. Phinney A. L.. (2006). Cyclohexanehexol-based inhibitors of Ab-aggregation prevent and reverse Alzheimer-like features in a transgenic model of Alzheimer disease. Nat. Med. 12, 801– 808. 10.1038/nm1423 16767098 · DOI
  85. Michaud M. Balardy L. Moulis G. Gaudin C. Peyrot C. Vellas B.. (2013b). Proinflammatory cytokines, aging and age-related diseases. J. Am. Med. Dir. Assoc. 14, 877– 882. 10.1016/j.jamda.2013.05.009 23792036 · DOI · Paper page
  86. Monsonego A. Maron R. Zota V. Selkoe D. J. Weiner H. L. (2001). Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer’s disease. Proc. Natl. Acad. Sci. U S A 98, 10273– 10278. 10.1073/pnas.191118298 11517335 PMC56951 · DOI
  87. Monsonego A. Zota V. Karni A. Krieger J. I. Bar-Or A. Bitan G.. (2003). Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112, 415– 422. 10.1172/jci18104 12897209 PMC166296 · DOI · Paper page
  88. Moody D. M. Brown W. R. Challa V. R. Anderson R. L. (1995). Periventricular venous collagenosis: association with leukoaraiosis. Radiology 194, 469– 476. 10.1148/radiology.194.2.7824728 7824728 · DOI
  89. Morgan D. (2011). Immunotherapy for Alzheimer’s disease. J. Intern. Med. 269, 54– 63. 10.1111/j.1365-2796.2010.02315.x 21158978 PMC3074967 · DOI · Paper page
  90. Muhs A. Hickman D. T. Pihlgren M. Chuard N. Giriens V. Meerschman C.. (2007). Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc. Natl. Acad. Sci. U S A 104, 9810– 9815. 10.1073/pnas.0703137104 17517595 PMC1887581 · DOI
  91. Nagele R. G. D’Andrea M. R. Lee H. Venkataraman V. Wang H. Y. (2003). Astrocytes accumulate Abeta 42 and give rise to astrocytic amyloid plaques in Alzheimer’s disease brains. Brain Res. 971, 197– 209. 10.1016/s0006-8993(03)02361-8 12706236 · DOI · Paper page
  92. Nascimento C. M. C. Teixeira C. V. L. Gobbi L. T. B. Gobbi S. Stella F. (2012). A controlled clinical trial on the effects of exercise on neuropsychiatric disorders and instrumental activities in women with Alzheimer’s disease. Rev. Bras. Fisioter. 16, 197– 204. 10.1590/s1413-35552012005000017 22499405 · DOI
  93. Nichol K. E. Poon W. W. Parachikova A. I. Cribbs D. H. Glabe C. G. Cotman C. W. (2008). Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J. Neuroinflammation 5: 13. 10.1186/1742-2094-5-13 18400101 PMC2329612 · DOI
  94. Nicolau C. Greferath R. Balaban T. S. Lazarte J. E. Hopkins R. J. (2002). A liposome-based therapeutic vaccine against β-amyloid plaques on the pancreas of transgenic NORBA mice. Proc. Natl. Acad. Sci. U S A 99, 2332– 2337. 10.1073/pnas.022627199 11842183 PMC122365 · DOI
  95. Nimmrich V. Eckert A. (2013). Calcium channel blockers and dementia. Br. J. Pharmacol. 169, 1203– 1210. 10.1111/bph.12240 23638877 PMC3831702 · DOI
  96. Okonkwo O. C. Schultz S. A. Oh J. M. Larson J. Edwards D. Cook D.. (2014). Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology 83, 1753– 1760. 10.1212/WNL.0000000000000964 25298312 PMC4239838 · DOI
  97. Olsson E. Karlström B. Kilander L. Byberg L. Cederholm T. Sjögren P. (2015). Dietary patterns and cognitive dysfunction in a 12-year follow-up study of 70 year old men. J. Alzheimers Dis. 43, 109– 119. 10.3233/JAD-140867 25062901 · DOI
  98. Origlia N. Righi M. Capsoni S. Cattaneo A. Fang F. Stern D. M.. (2008). Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-β-mediated cortical synaptic dysfunction. J. Neurosci. 28, 3521– 3530. 10.1523/jneurosci.0204-08.2008 18367618 PMC6670592 · DOI
  99. Pan W. Kastin A. J. (2014). Can sleep apnea cause Alzheimer’s disease? Neurosci. Biobehav. Rev. 47, 656– 669. 10.1016/j.neubiorev.2014.10.019 25451764 · DOI
  100. Paoli A. Bianco A. Damiani E. Bosco G. (2014). Ketogenic diet in neuromuscular and neurodegenerative diseases. Biomed. Res. Int. 2014: 474296. 10.1155/2014/474296 25101284 PMC4101992 · DOI
  101. Pardridge W. M. (2007). Blood-brain barrier delivery. Drug Discov. Today 12, 54– 61. 10.1016/j.drudis.2006.10.013 17198973 · DOI · Paper page
  102. Pettersen J. A. Sathiyamoorthy G. Gao F. Q. Szilagyi G. Nadkarni N. K. St George-Hyslop P.. (2008). Microbleed topography, leukoaraiosis and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch. Neurol. 65, 790– 795. 10.1001/archneur.65.6.790 18541799 · DOI
  103. Qiu W. Q. Folstein M. F. (2006). Insulin, insulin degrading enzyme and amyloid-beta peptide in Alzheimer’s disease; review and hypothesis. Neurobiol. Aging 27, 190– 198. 10.1016/j.neurobiolaging.2005.01.004 16399206 · DOI
  104. Querfurth H. W. LaFerla F. M. (2010). Alzheimer’s disease. N. Engl. J. Med. 362, 329– 344. 10.1056/NEJMra0909142 20107219 · DOI · Paper page
  105. Rajapaksha T. W. Eimer W. A. Bozza T. C. Vassar R. (2011). The Alzheimer ’s β-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. Mol. Neurodegener. 6: 88. 10.1186/1750-1326-6-88 22204380 PMC3269394 · DOI
  106. Reppert S. M. Weaver D. R. (2001). Molecular analysis of mammalian circadian rhythms. Annu. Rev. Physiol. 63, 647– 676. 10.1146/annurev.physiol.63.1.647 11181971 · DOI · Paper page
  107. Revesz T. Ghiso J. Lashley T. Plant G. Rostagno A. Frangione B.. (2003). Cerebral amyloid angiopathies: a pathologic, biochemical and genetic view. J. Neuropathol. Exp. Neurol. 62, 885– 898. 14533778
  108. Revesz T. Holton J. L. Lashley T. Plant G. Rostagno A. Ghiso J.. (2002). Sporadic and familial cerebral amyloid angiopathies. Brain Pathol. 12, 343– 357. 10.1111/j.1750-3639.2002.tb00449.x 12146803 PMC8095796 · DOI
  109. Reynolds C. A. Gatz M. Prince J. A. Berg S. Pedersen N. L. (2010). Serum lipid levels and cognitive change in late life. J. Am. Geriatr. Soc. 58, 501– 509. 10.1111/j.1532-5415.2010.02739.x 20398119 PMC2913576 · DOI
  110. Roher A. E. Esh C. Kokjohn T. A. Kalback W. Luehrs D. C. Seward J. D.. (2003). Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer’s disease. Arterioscler. Thromb. Vasc. Biol. 23, 2055– 2062. 10.1161/01.atv.0000095973.42032.44 14512367 · DOI
  111. Ross R. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801– 809. 10.1038/362801a0 8479518 · DOI
  112. Sabbagh M. N. Agro A. Bell J. Aisen P. S. Schweizer E. Galasko D. (2011). PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer’s disease. Alzheimer Dis. Assoc. Disord. 25, 206– 212. 10.1097/wad.0b013e318204b550 21192237 PMC3346183 · DOI
  113. Sagare A. P. Bell R. D. Zlokovic B. V. (2013). Neurovascular defects and faulty amyloid-b vascular clearance in Alzheimer’s disease. J. Alzheimers Dis. 33, S87– S100 10.3233/JAD-2012-129037 22751174 PMC4416477 · DOI
  114. Saito S. Ihara M. (2014). New therapeutic approaches for Alzheimer’s disease and cerebral amyloid angiopathy. Front. Aging Neurosci. 6: 290. 10.3389/fnagi.2014.00290 25368578 PMC4202741 · DOI
  115. Sakurai H. Hanyu H. Sato T. Kume K. Hirao K. Kanetaka H.. (2013). Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer’s disease and cerebrovascular disease: a pilot study. Geriatr. Gerontol. Int. 13, 90– 97. 10.1111/j.1447-0594.2012.00866.x 22672107 · DOI
  116. Samadi H. Sultzer D. (2011). Solanezumab for Alzheimer’s disease. Expert Opin. Biol. Ther. 11, 787– 798. 10.1517/14712598.2011.578573 21504387 · DOI
  117. Selkoe D. J. (2001). Alzheimer’s disease: genes, proteins and therapy. Physiol. Rev. 81, 741– 766. 11274343
  118. Sengillo J. D. Winkler E. A. Walker C. T. Sullivan J. S. Johnson M. Zlokovic B. V. (2013). Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer’s disease. Brain Pathol. 23, 303– 310. 10.1111/bpa.12004 23126372 PMC3628957 · DOI · Paper page
  119. Sigurdsson E. M. Knudsen E. Asuni A. Fitzer-Attas C. Sage D. Quartermain D.. (2004). An attenuated immune response is sufficient to enhance cognition in an Alzheimer’s disease mouse model immunized with amyloid-β derivatives. J. Neurosci. 24, 6277– 6282. 10.1523/jneurosci.1344-04.2004 15254082 PMC6729550 · DOI
  120. Sperling R. A. Aisen P. S. Beckett L. A. Bennett D. A. Craft S. Fagan A. M.. (2011). Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 280– 292. 10.1016/j.jalz.2011.03.003 21514248 PMC3220946 · DOI · Paper page
  121. Spira A. P. Gamaldo A. A. An Y. Wu M. N. Simonsick E. M. Bilgel M.. (2013). Self-reported sleep and β-amyloid deposition in community-dwelling older adults. JAMA Neurol. 70, 1537– 1543. 10.1001/jamaneurol.2013.4258 24145859 PMC3918480 · DOI · Paper page
  122. Sterniczuk R. Dyck R. H. Laferla F. M. Antle M. C. (2010). Characterization of the 3xTg-AD mouse model of Alzheimer’s disease: part 1. Circadian changes. Brain Res. 1348, 139– 148. 10.1016/j.brainres.2010.05.013 20471965 · DOI
  123. Stone J. Kleijn H. J. Dockendorf M. Ma L. Palcza J. Tseng J. (2013). Consistency of Bace inhibitor-mediated brain amyloid production inhibition by MK-8931 in Alzheimer’s disease patients and healthy young adults. Alzheimers Dement. J. Alzheimers Assoc. 9, P690– P691 10.1016/j.jalz.2013.04.362 · DOI
  124. Stranahan A. M. Martin B. Maudsley S. (2012). Anti-inflammatory effects of physical activity in relationship to improved cognitive status in humans and mouse models of Alzheimers disease. Curr. Alzheimer Res. 9, 86– 92. 10.2174/156720512799015019 22329653 PMC4445413 · DOI
  125. Suttanon P. Hill K. D. Said C. M. Williams S. B. Byrne K. N. LoGiudice D.. (2013). Feasibility, safety and preliminary evidence of the effectiveness of a home-based exercise programme for older people with Alzheimer’s disease: a pilot randomized controlled trial. Clin. Rehabil. 27, 427– 438. 10.1177/0269215512460877 23117349 · DOI
  126. Szentistványi I. Patlak C. S. Elliss R. A. Cserr H. F. (1984). Drainage of interstitial fluid from different regions of rat brain. Am. J. Physiol. 246, F835– F844. 6742132
  127. Takakura S. Sogabe K. Satoh H. Mori J. Fujiwara T. Totsuka Z.. (1992). Nilvadipine as a neuroprotective calcium entry blocker in a rat model of global cerebral ischemia. A comparative study with nicardipine hydrochloride. Neurosci. Lett. 141, 199– 202. 10.1016/0304-3940(92)90894-d 1436634 · DOI
  128. Tang B. L. Chua C. E. L. (2008). SIRT1 and neuronal diseases. Mol. Aspects Med. 29, 187– 200. 10.1016/j.mam.2007.02.001 17397914 · DOI
  129. Tanzi R. E. Moir R. D. Wagner S. L. (2004). Clearance of Alzheimer’s Aβ peptide: the many roads to perdition. Neuron 43, 605– 608. 10.1016/s0896-6273(04)00533-1 15339642 · DOI
  130. Thal D. R. Griffin W. S. T. de Vos R. A. Ghebremedhin E. (2008). Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease. Acta Neuropathol. 115, 599– 609. 10.1007/s00401-008-0366-2 18369648 · DOI · Paper page
  131. Thal D. R. Sassing I. Schultz C. Haas C. Braak E. Braak H. (1999). Fleecy amyloid deposits in the internal layers of the human entorhinal cortex are comprised of N-terminal truncated fragments of Aβ. J. Neuropathol. Exp. Neurol. 58, 210– 216. 10.1097/00005072-199902000-00010 10029103 · DOI
  132. Tolppanen A.-M. Solomon A. Soininen H. Kivipelto M. (2012). Midlife vascular risk factors and Alzheimer’s disease: evidence from epidemiological studies. J. Alzheimers Dis. 32, 531– 540. 10.3233/JAD-2012-120802 22842867 · DOI
  133. Vassar R. Bennett B. D. Babu-Khan S. Kahn S. Mendiaz E. A. Denis P.. (1999). β-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735– 741. 10.1126/science.286.5440.735 10531052 · DOI · Paper page
  134. Venturelli M. Scarsini R. Schena F. (2011). Six-month walking program changes cognitive and ADL performance in patients with Alzheimer. Am. J. Alzheimers Dis. Other Demen. 26, 381– 388. 10.1177/1533317511418956 21852281 PMC10845333 · DOI
  135. Verbeek M. M. Van Nostrand W. E. Otte-Höller I. Wesseling P. De Waal R. M. (2000). Amyloid-β-induced degeneration of human brain pericytes is dependent on the apolipoprotein E genotype. Ann. N Y Acad. Sci. 903, 187– 199. 10.1111/j.1749-6632.2000.tb06368.x 10818507 · DOI
  136. Videnovic A. Lazar A. S. Barker R. A. Overeem S. (2014). ‘The clocks that time us’-circadian rhythms in neurodegenerative disorders. Nat. Rev. Neurol. 10, 683– 693. 10.1038/nrneurol.2014.206 25385339 PMC4344830 · DOI
  137. Vidoni E. D. Van Sciver A. Johnson D. K. He J. Honea R. Haines B.. (2012). A community-based approach to trials of aerobic exercise in aging and Alzheimer’s disease. Contemp. Clin. Trials 33, 1105– 1116. 10.1016/j.cct.2012.08.002 22903151 PMC3468654 · DOI
  138. Voss M. W. Vivar C. Kramer A. F. van Praag H. (2013). Bridging animal and human models of exercise-induced brain plasticity. Trends Cogn. Sci. 17, 525– 544. 10.1016/j.tics.2013.08.001 24029446 PMC4565723 · DOI · Paper page
  139. Wan R. Weigand L. A. Bateman R. Griffioen K. Mendelowitz D. Mattson M. P. (2014). Evidence that BDNF regulates heart rate by a mechanism involving increased brainstem parasympathetic neuron excitability. J. Neurochem. 129, 573– 580. 10.1111/jnc.12656 24475741 PMC4137462 · DOI
  140. Wang J. Ho L. Qin W. Rocher A. B. Seror I. Humala N.. (2005). Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer’s disease. FASEB J. 19, 659– 661. 10.1096/fj.04-3182fje 15650008 · DOI
  141. Wang P. Olbricht W. L. (2011). Fluid mechanics in the perivascular space. J. Theor. Biol. 274, 52– 57. 10.1016/j.jtbi.2011.01.014 21241713 · DOI
  142. Weksler M. E. Relkin N. Turkenich R. LaRusse S. Zhou L. Szabo P. (2002). Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontology 37, 943– 948. 10.1016/s0531-5565(02)00029-3 12086704 · DOI
  143. Weller R. O. (2005). Microscopic morphology and histology of the human meninges. Morphologie 89, 22– 34. 10.1016/s1286-0115(05)83235-7 15943078 · DOI
  144. Weller R. O. Boche D. Nicoll J. A. R. (2009). Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy. Acta Neuropathol. 118, 87– 102. 10.1007/s00401-009-0498-z 19234858 · DOI · Paper page
  145. Weller R. O. Galea I. Carare R. O. Minagar A. (2010). Pathophysiology of the lymphatic drainage of the central nervous system: implications for pathogenesis and therapy of multiple sclerosis. Pathophysiology 17, 295– 306. 10.1016/j.pathophys.2009.10.007 19954936 · DOI
  146. Weller R. O. Subash M. Preston S. D. Mazanti I. Carare R. O. (2008). Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol. 18, 253– 266. 10.1111/j.1750-3639.2008.00133.x 18363936 PMC8095597 · DOI
  147. Wiessner C. Wiederhold K. H. Tissot A. C. Frey P. Danner S. Jacobson L. H.. (2011). The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J. Neurosci. 31, 9323– 9331. 10.1523/JNEUROSCI.0293-11.2011 21697382 PMC6623465 · DOI
  148. Wilcock D. M. Rojiani A. Rosenthal A. Levkowitz G. Subbarao S. Alamed J.. (2004). Passive amyloid immunotherapy clears amyloid and transiently activated microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 24, 6144– 6151. 10.1523/jneurosci.1090-04.2004 15240806 PMC6729674 · DOI
  149. Winblad B. Andreasen N. Minthon L. Floesser A. Imbert G. Dumortier T.. (2012). Safety, tolerability and antibody response of active Aβ immunotherapy with CAD106 in patients and with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 11, 597– 604. 10.1016/s1474-4422(12)70140-0 22677258 · DOI
  150. Winchester J. Dick M. B. Gillen D. Reed B. Miller B. Tinklenberg J.. (2013). Walking stabilizes cognitive functioning in Alzheimer’s disease (AD) across one year. Arch. Gerontol. Geriatr. 56, 96– 103. 10.1016/j.archger.2012.06.016 22959822 PMC3766353 · DOI
  151. Witte A. V. Fobker M. Gellner R. Knecht S. Flöel A. (2009). Caloric restriction improves memory in elderly humans. Proc. Natl. Acad. Sci. U S A 106, 1255– 1260. 10.1073/pnas.0808587106 19171901 PMC2633586 · DOI · Paper page
  152. Wu P. Shen Q. Dong S. Xu Z. Tsien J. Z. Hu Y. (2008). Calorie restriction ameliorates neurodegenerative phenotypes in forebrain-specific presenilin-1 and presenilin-2 double knockout mice. Neurobiol. Aging 29, 1502– 1511. 10.1016/j.neurobiolaging.2007.03.028 17499883 · DOI
  153. Wyatt A. R. Yerbury J. J. Dabbs R. A. Wilson M. R. (2012). Roles of extracellular chaperones in amyloidosis. J. Mol. Biol. 421, 499– 516. 10.1016/j.jmb.2012.01.004 22248589 · DOI
  154. Yan S. D. Chen X. Fu J. Chen M. Zhu H. Roher A.. (1996). RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature 382, 685– 691. 10.1038/382685a0 8751438 · DOI · Paper page
  155. Yan S. S. Chen D. Yan S. Guo L. Chen J. X. (2012). RAGE is a key cellular target for Aβ-induced perturbation in Alzheimer’s disease. Front. Biosci. (Schol. Ed.) 4, 240– 250. 10.2741/S265 22202057 PMC3687351 · DOI
  156. Yanagisawa D. Shirai N. Amatsubo T. Taguchi H. Hirao K. Urushitani M.. (2010). Relationship between tautomeric stuctures of curcumin derivatives and their Abeta-binding activities in the context of therapies for Alzheimer’s disease. Biomaterials 31, 4179– 4185. 10.1016/j.biomaterials.2010.01.142 20181392 · DOI
  157. Yasojima K. Akiyama H. McGeer E. G. McGeer P. L. (2001). Reduced neprilysin in high plaque areas of Alzheimer’s disease brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci. Lett. 297, 97– 100. 10.1016/s0304-3940(00)01675-x 11121879 · DOI
  158. Zelinski E. L. Deibel S. H. McDonald R. J. (2014). The trouble with circadian clock dysfunction: multiple deleterious effects on the brain and body. Neurosci. Biobehav. Rev. 40, 80– 101. 10.1016/j.neubiorev.2014.01.007 24468109 · DOI
  159. Zhou L. Barão S. Laga M. Bockstael K. Borgers M. Gijsen H.. (2012). The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. J. Biol. Chem. 287, 25927– 25940. 10.1074/jbc.M112.377465 22692213 PMC3406677 · DOI · Paper page

Cited by

Sorted by citations

See all 26

Metadata

Authors
Morrone, C. D., Liu, M., Black, S. E., & McLaurin, J.
Venue
Frontiers in Aging Neuroscience
Publisher
Frontiers Media SA
Published
2015-05-05
Volume
7
ISSN
1663-4365
DOI
10.3389/fnagi.2015.00064
PMC
PMC4419721
Cited by
26
References
32

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review